Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study

Abdelhamid, Thoraya; Samra, Mohamed; Ramadan, Hanan; Mehessin, Marowa; Mokhtar, Nadia

doi:10.1016/j.jnci.2011.07.003

Cited by 23 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pertinent clinical data, including age, gender, initial presenting symptoms, laboratory examination findings, pathologic diagnosis, involved organs, International Prognostic Index (IPI) score (11,12), detailed treatment modalities, time to death and the date of the last follow-up, were collected for the analysis. Additional workup examinations included bone marrow biopsies, plain X-ray films of the bone, computed tomography (CT), magnetic resonance imaging (MRI) of the bone lesion(s) and positron-emission tomography (PET).…”

Section: Patientsmentioning

confidence: 99%

Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years

Liu

Gau

et al. 2014

Intern. Med.

View full text Add to dashboard Cite

Objective Primary bone lymphoma is a rare disorder, accounting for less than 1% of all cases of malignant lymphoma. Primary bony diffuse large B-cell lymphoma (PBDLBCL) is the most common histological type. In our study, a favorable response and lower risk of emergent surgery were observed following the administration of systemic chemotherapy with or without rituximab. Methods Patients diagnosed with malignant lymphoma at our hospital between 2000 and 2011 were evaluated for PBDLBCL. Pertinent data, including the clinical presentation, histological type, treatment modalities, long-term outcome, survival curve and prognostic factors, were analyzed. Results Twenty-four patients with a median age of 63 years were diagnosed with PBDLBCL. A complete response (CR) was achieved in 58.4% (n=14) of the patients. With treatment of the disease, nine of 10 patients with initially impending pathological bone fractures ultimately did not undergo surgery. The median follow-up duration was 48 months. Two patients experienced disease relapse. In a Kaplan-Meier analysis, the 5-year overall survival (OS) and disease-free survival (DFS) rates were 66.7% and 77.8%, respectively. In the univariate analyses, the significantly favorable prognostic factors for OS were an International Prognostic Index (IPI) score of <3, an age of 60 years, a performance status with an Eastern Cooperative Oncology (ECOG) score of <2, a CR and chemotherapy 6 cycles. For DFS, a CR was the only favorable factor. In the multivariate analysis, a CR was the only independent factor for both OS and DFS. Conclusion Our study confirms the good prognosis of this rare disorder. Once a CR is achieved, even elderly patients may exhibit long-term survival, possibly obviating the need for surgery for less severe bone lesions.

show abstract

Section: Patientsmentioning

confidence: 99%

Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years

Liu

Gau

et al. 2014

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…[13] It seems that demonstration of bcl-12 expression should always raise suspicion of a systemic lymphoma involving the skin secondarily and unfavorable course of disease. [2,7] However, as seen in the present case, the disease ran an indolent course with no intracranial invasion despite of bcl-12 expression.…”

Section: Discussionmentioning

confidence: 99%

A 92-year-old man with primary cutaneous diffuse large B-cell non-Hodgkin's lymphoma manifesting as a giant scalp mass

Liao

Yang²,

Liu³

et al. 2017

Medicine

View full text Add to dashboard Cite

Rationale:Primary cutaneous non-Hodgkin's lymphoma (NHL) is an uncommon entity, representing 10% of all extranodal NHLs. Among all cutaneous sites, the scalp is a rare site of representation.Patient concerns:A 92-year-old Chinese man visited our hospital with a multiple-nodular huge scalp mass on the right parieto-occipital regions. The mass was of 7-month duration and progressively enlarging in size.Diagnoses:On the basis of the result of biopsy, diffuse large B-cell NHL was diagnosed.Interventions:The mass was partially resected by surgery and no further treatment was conducted due to the advanced age and poor physical status.Outcomes:The tumor relapsed in situ after 6 months and the patient died after 2 years.Lessons:This case highlighted the limited access to standard treatment options in patients with advanced age. A thorough examination is necessary to decide upon the treatment for the primary cutaneous lymphoma.

show abstract

“…Indolent lymphomas progress slowly and have long-term survival; while aggressive lymphomas may have poor prognosis that progress in a short time [1]. International prognostic index (IPI) is still known as the effective prognostic factor for aggressive lymphomas today [3], [6]. But more and more researchers have focused on the effect of inflammation and immune-related gene polymorphisms on pathogenesis and prognosis of NHL.…”

Section: Discussionmentioning

confidence: 99%

“…But a number of patients do not achieve complete remission or relapse after chemotherapy. Several studies have shown that the courses of NHLs are variable, and NHL survival patterns vary by subtypes, suggesting different prognostic risk factors for NHL histological subtypes [3], [4], [5]. International prognostic index (IPI) model was developed for predicting outcome in patients with aggressive NHL in 1993, which pointed out that more than 60-year-old, advanced tumor stage, poor performance score, extranodal involvement and elevated lactate dehydrogenase (LDH) were adverse prognostic factors for NHL [6].…”

Section: Introductionmentioning

confidence: 99%

Lymphotoxin Alpha (LTA) Polymorphism Is Associated with Prognosis of Non-Hodgkin’s Lymphoma in a Chinese Population

et al. 2013

View full text Add to dashboard Cite

BackgroundNon-Hodgkin’s lymphoma (NHL) has been widely reported to be associated with autoimmune and pro-inflammatory response, and genetic polymorphisms of candidate genes involved in autoimmune and pro-inflammatory response may influence the survival and prognosis of NHL patients. To evaluate the role of such genetic variations in prognosis of NHL, we conducted this study in a Chinese population.MethodsWe used the TaqMan assay to genotype six single nucleotide polymorphisms (SNPs) (TNF rs1799964T>C, LTA rs1800683G>A, IL-10 rs1800872T>G, LEP rs2167270G>A, LEPR rs1327118C>G, TNFAIP8 rs1045241C>T) for 215 NHL cases. Kaplan-Meier analysis was performed to compare progression free survival among two common genotypes. Cox proportional hazard models were used to identify independent risk factors.ResultsWe observed that LTA rs1800683G>A was significantly associated with risk of progression or relapse in NHL patients (HR = 1.63, 95%CI = 1.06–2.51; P = 0.028), particularly in Diffuse large B cell lymphoma (DLBCL) cases (HR = 1.50, 95%CI = 1.10–2.04, P = 0.01). Both univariate and multivariate Cox regression analysis showed that in DLBCL patients, Ann Arbor stage III/IV, elevated LDH level before treatment and LTA rs1800683 AA genotype carrier were independent risk factors for progression or relapse. While in NK/T cell lymphoma, Ann Arbor stage III/IV and elevated β2-MG level before treatment indicated poorer prognosis.ConclusionsThe polymorphism of LTA rs1800683G>A contributes to NHL prognosis in a Chinese population. Further large-scale and well-designed studies are needed to confirm these results.

show abstract

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study

Cited by 23 publications

References 20 publications

Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years

Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years

A 92-year-old man with primary cutaneous diffuse large B-cell non-Hodgkin's lymphoma manifesting as a giant scalp mass

Lymphotoxin Alpha (LTA) Polymorphism Is Associated with Prognosis of Non-Hodgkin’s Lymphoma in a Chinese Population

Contact Info

Product

Resources

About